Kathy A. Steece-Collier, Ph.D.
Affiliations: | Translational Science & Molecular Medicine | Michigan State University, East Lansing, MI |
Area:
Parkinson's disease / dyskinesias / synaptic reorganizationGoogle:
"Kathy Steece-Collier"Mean distance: 16.92 (cluster 6) | S | N | B | C | P |
Collaborators
Sign in to add collaborator| Jack W. Lipton | collaborator | Michigan State | |
| Caryl E. Sortwell | collaborator | Michigan State |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stoll AC, Kemp CJ, Patterson JR, et al. (2024) Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions. Neurobiology of Disease. 106411 |
| Patterson JR, Kochmanski J, Stoll AC, et al. (2024) Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils. Npj Parkinson's Disease. 10: 7 |
| Collier TJ, Begg L, Stancati JA, et al. (2023) Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine. Experimental Neurology. 114522 |
| Caulfield ME, Vander Werp MJ, Stancati JA, et al. (2023) Downregulation of striatal Ca1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age. Neurobiology of Disease. 181: 106111 |
| Caulfield ME, Manfredsson FP, Steece-Collier K. (2023) The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease. Handbook of Experimental Pharmacology |
| Patterson JR, Hirst WD, Howe JW, et al. (2022) Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein. Npj Parkinson's Disease. 8: 61 |
| Caulfield ME, Stancati JA, Steece-Collier K. (2021) Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. Journal of Visualized Experiments : Jove |
| Cole TA, Zhao H, Collier TJ, et al. (2021) α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. Jci Insight. 6 |
| Miller KM, Patterson JR, Kochmanski J, et al. (2021) Striatal afferent BDNF is disrupted by synucleinopathy and partially restored by STN DBS. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience |
| Mercado NM, Stancati JA, Sortwell CE, et al. (2020) The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats. Neurobiology of Disease. 105175 |